Therapeutics formulated to target cancer stem cells: Is it in our future?

Cancer Cell International

Shaker A Mousa¹  Stephanie Clayton² 

[1] College of Medicine, King Saud University, Riyadh, 11461, Saudi Arabia;The Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY, 12144, USA

关键词: Signaling Pathways;    Cancer Recurrence;    Chemoresistance;    Targeted Therapy;    Microenvironment;    Cell Surface Markers;    Molecular Signature;    Cancer Stem Cell Like;    Cancer Stem Cell;   

Others  :  795579
DOI  :  10.1186/1475-2867-11-7

 received in 2010-07-17, accepted in 2011-03-25,  发布年份 2011

【 摘 要 】

With the political, social and financial drives for cancer research, many advances have been made in the treatment of many different cancer types. For example, given the increase in awareness, early detection, and treatment of breast and prostate cancers, we have seen substantial increases in survival rates. Unfortunately there are some realms of cancer that have not seen these substantial advancements, largely due to their rapid progression and the inability to specifically target therapy.

The hypothesis that cancers arise from a small population of cells, called cancer stem cells (CSCs), is gaining more popularity amongst researchers. There are, however, still many skeptics who bring into question the validity of this theory. Many skeptics believe that there is not a specific subset of cells that originate with these characteristics, but that they develop certain features over time making them more resistant to conventional therapy. It is theorized that many of the relapses occurring after remission are due to our inability to destroy the self-renewing CSCs. This central idea, that CSCs are biologically different from all other cancer cells, has directed research towards the development of therapy to target CSCs directly. The major dilemma in targeting therapy in myeloproliferative disorders, malignancies of the central nervous system or malignancies in general, is the inability to target CSCs as opposed to normal stem cells. However, with the recent advances in the identifications of unique molecular signatures for CSCs along with ongoing clinical trials targeting CSCs, it is possible to use targeted nanotechnology-based strategies in the management of different types of cancers.

【 授权许可】

   
2011 Clayton and Mousa; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-7.
• [2]Tang C, Ang BT, Pervaiz S: Cancer stem cell: target for anti-cancer therapy. FASEB J 2007, 21(14):3777-85.
• [3]Karp JE, ed: Acute Myelogenous Leukemia. Humana Press: Totowa; 2007.
• [4]ten Cate B, et al.: Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets 2010, 11(1):95-110.
• [5]ten Cate B, et al.: A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23(8):1389-97.
• [6]Milligan DW, et al.: Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006, 135(4):450-74.
• [7]Leith CP, et al.: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89(9):3323-9.
• [8]Sievers EL, et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93(11):3678-84.
• [9]Sievers EL, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19(13):3244-54.
• [10]Larson RA, et al.: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104(7):1442-52.
• [11]Lowenberg B, et al.: Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010, 115(13):2586-91.
• [12]Walter RB, et al.: CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007, 109(10):4168-70.
• [13]Jawad M, et al.: Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24(1):74-80.
• [14]Zhao X, et al.: Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010, 95(1):71-8.
• [15]van Rhenen A, et al.: The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110(7):2659-66.
• [16]Tang R, et al.: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 2008, 8:51. BioMed Central Full Text
• [17]Latagliata R, et al.: Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008, 143(5):681-9.
• [18]Robert G, Fenton DLL: Cancer Cell Biology and Angiogenesis. The McGraw-Hill Companies, Inc; 2008.
• [19]Martelli AM, et al.: The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol 2010, 25(5):669-80.
• [20]Martelli AM, et al.: Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009, 18(9):1333-49.
• [21]Sirolimus.
• [22]Bleau AM, et al.: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4(3):226-35.
• [23]Goodell MA, et al.: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183(4):1797-806.
• [24]Bapat S, ed: Cancer Stem Cells: Identification and Targets. John Wiley & Sons: Hoboken; 2009:29-45. 73-81
• [25]Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-510.
• [26]Muranyi AL, Dedhar S, Hogge DE: Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res 2010, 34(10):1358-65.
• [27]Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28(6):1075-83.
• [28]Hess G, et al.: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27(23):3822-9.
• [29]Hainsworth JD, et al.: Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 2010, 28(13):2131-6.
• [30]Ghobrial IM, et al.: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010, 28(8):1408-14.
• [31]Pandolfi PP: Breast cancer--loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351(22):2337-8.
• [32]Peng C, et al.: PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010, 115(3):626-35.
• [33]Von Hoff DD, et al.: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(12):1164-72.
• [34]Rudin CM, et al.: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361(12):1173-8.
• [35]Hofmann I, et al.: Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4(6):559-67.
• [36]Fang J, Seki T, Maeda H: Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009, 61(4):290-302.
• [37]Kotamraju S, Williams CL, Kalyanaraman B: Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007, 67(15):7386-94.
• [38]Chen R, et al.: Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med Oncol 2010.
• [39]Li R, et al.: P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010, 4(3):1399-408.
• [40]Li GY, et al.: Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother 2009, 63(8):566-70.
• [41]Balyasnikova IV, et al.: Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One 2010, 5(3):e9750.
• [42]Wei Z, et al.: Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res 2009, 28:141. BioMed Central Full Text
• [43]Mishima K, et al.: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001, 61(14):5349-54.
• [44]Morrison R, et al.: Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011, 2011:941876.